



Theradiag announces its 2021 financial calendar

Croissy-Beaubourg, December 15, 2020, 5.45pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in *in vitro* diagnostics of autoimmune diseases and theranostics, today announces its schedule for the publication of financial information for 2021.

Events	Dates*
2020 Full-Year Annual Revenue	Monday February 1, 2021
2020 Full-Year Results	Monday March 22, 2021
Annual General Meeting	Thursday May 6, 2021
2021 First-Half Revenue	Monday July 19, 2021
2021 First-Half Results	Monday September 20, 2021

(*) Subject to modifications. Press releases will be published before market opening.

About Theradiag

Theradiag is the market leader in biotherapy monitoring. Capitalizing on its expertise in the diagnostics market, the Company has been developing, manufacturing and marketing innovative *in vitro* diagnostic (IVD) tests for over 30 years.

Theradiag pioneered “theranostics” testing (combining therapy with diagnosis), which measures the efficacy of biotherapy in the treatment of chronic inflammatory diseases. Going beyond mere diagnosis, theranostics aims to help clinicians set up “customized treatment” for each patient. This method favors the individualization of treatment, evaluation of its efficacy and the prevention of drug resistance. In response to this challenge, Theradiag develops and markets the CE-marked TRACKER® range, a comprehensive solution of inestimable medical value.

The Company is based in Marne-la-Vallée, near Paris, has operations in over 70 countries and employs over 60 people. In 2019, the Company posted revenue of €9.6 million. The Theradiag share is listed on Euronext Growth Paris (ISIN: FR0004197747) and is eligible for the French PEA-PME personal equity plan.

For more information about Theradiag, please visit our website: www.theradiag.com





Theradiag

Bertrand de Castelnu

CEO/Managing Director

Tel.: +33 (0)1 64 62 10 12

contact@theradiag.com

NewCap

Financial Communications &

Investor Relations

Louis-Victor Delouvrier

Quentin Massé

Tel.: +33 (0)1 44 71 94 94

theradiag@newcap.eu

NewCap

Media Relations

Nicolas Mérieau

Tel.: +33 (0)1 44 71 94 98

nmerigeau@newcap.fr